

Amendments to the Specification:

Please replace the paragraph beginning on page 1, line 6 with the following amended paragraph:

This application is a continuation of U.S. Application No. 09/072,967, filed May 5, 1998, now U.S. Patent No. 6,592,877, which is a continuation-in-part of U.S. Application No. 09/025,197, filed February 18, 1998, now abandoned; which is a continuation-in-part of U.S. Application No. 08/942,578, filed October 1, 1997, now abandoned; which is a continuation-in-part of U.S. Application No. 08/818,112, filed March 13, 1997, now U.S. Patent No. 6,290,969; which is a continuation-in-part of U.S. Application No. 08/730,510, filed October 11, 1996, now abandoned; which claims priority from PCT Application No. PCT/US 96/14674, filed August 30, 1996; and is a continuation-in-part of U.S. Application No. 08/680,574, filed July 12, 1996, now abandoned; which is a continuation-in-part of U.S. Application No. 08/659,683, filed June 5, 1996, now abandoned; which is a continuation-in-part of U.S. Application No. 08/620,874, filed March 22, 1996, now abandoned; which is a continuation-in-part of U.S. Application No. 08/533,634, filed September 22, 1995, now abandoned; which is a continuation-in-part of U.S. Application No. 08/523,436, filed September 1, 1995, now abandoned, each of which is herein incorporated by reference in their entirety.

Please add the following new paragraphs beginning at page 7, line 19:

FIG. 10 illustrates the percent survival after administration of saline, AS2, AS2+Mtb39, AS2+Mtb39+Mtb32, or BCG.

FIGS. 11A and B show the results of aerosol TB challenge of vaccinated guinea pigs.

FIG. 12 shows the results of DNA immunized mice challenged with aerosol TB (lung CFU).